Empower your patients through early detection
Understanding Health Through Breath
Nanotechnology, chemistry and machine learning converge in the MyBreathPrint® system, advancing the potential for physicians to classify patients quickly throughout their journey. Serving as your copilot, MyBreathPrint can help you accurately diagnose, make more informed decisions, and provide the best treatment options for your patients as possible.
While Vocxi Health has initially developed MyBreathPrint to detect lung cancer, with its one hardware design MyBreathPrint is scalable and, through its machine learning platform, customizable to detect a wide variety of diseases, ailments and health issues.
other cancers
infectious deseases
emergency medicine
Clinical Studies
With its nanosensor array’s parts per billion-level sensitivity and machine learning approach, MyBreathPrint has demonstrated successful early lung cancer detection through three Institutional Review Board-approved human clinical studies. It was proven four times more accurate than other screening approaches in the detection of stage-one lung cancer.
Of the 200 people who have used the device, 100 percent responded positively to its ease of use. The accessibility, accuracy and adaptability of MyBreathPrint have the potential to transform the patient journey and save millions of lives, one patient at a time.
Our Mission Is to Create the Most Accessible and Accurate Breath Sensor to Understand Patient Health As Early As Possible.
The Vocxi Health Value-add
MyBreathPrint through the care pathways
VALUE ADD TO
Very Low-risk Patients
The current care pathway is surveillance wait and see until symptoms arise.
MyBreathPrint: Give the provider additional information at 3-, 6- or 12-month intervals.
PROVIDER: Perform biopsy sooner and catch the cancer sooner.
PAYER: Limiting risk of an unnecessary biopsy with a negative result.
PATIENT: Perform biopsy sooner and catch the cancer sooner.
VALUE ADD TO
Medium-risk Patients
The current care pathway is filled with uncertainty: CT scans, potential biopsy or more surveillance.
MyBreathPrint: It gives the provider an informed path to biopsy or further surveillance months.
PROVIDER: Informed decision about biopsy vs. surveillance.
PAYER: Reduce non-responder drug costs.
PATIENT Avoid debt-burden of expensive treatments if non-responder.
VALUE ADD TO
High-risk Patients
The current care pathway is often an invasive treatment followed by invasive follow-ups.
MyBreathPrint: Disease monitoring can become a noninvasive, simpler post-treatment/drug monitoring solution.
PROVIDER: Informed decision about biopsy vs. surveillance .
PAYER: Reduce non-responder drug costs.
PATIENT: Avoid debt-burden of expensive treatments if non-responder.
The patient journey difference
How MyBreathPrint Transforms Processes and Outcomes
The simple-to-use elegance of the MyBreathPrint system has the potential to serve as the physician’s copilot, helping them improve the patient journey through more accurate diagnosis, more informed decision-making and providing the best treatment solutions possible.
News & Resources
Keep Up to Date with Vocxi Health and the Latest Scientific News
A Breath-through Solution
Learn How and Why Vocxi Health is Transforming the Patient Journey Through Early Disease Detection!
the Breath Solution
The Vocxi Why: to eliminate late-stage diagnosis and save millions of lives, so you know!
science & technology
Learn how with its powerfully sensitive nanosensors, MyBreathPrint connects VOC signals to diseases.
